文献速递核素与放射性配体治疗放射性药物与辐射防护

多中心回顾性研究肽受体放射性核素治疗联合兰瑞肽治疗神经内分泌肿瘤的教训:需要标准化实践

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-02-15

PRELUDE研究为国际性、非干预性、回顾性、非比较性病历分析,纳入40例进展期转移性或局部晚期1或2级胃肠胰或肺神经内分泌肿瘤患者,评估兰瑞肽autogel/depot联合177Lu-DOTATOC或177Lu-DOTATATE的疗效与安全性。末次联合周期结束时无进展生存率为91.7%,末次随访时为95.0%;胃肠胰神经内分泌肿瘤患者最佳总体疗效为疾病稳定60.9%、部分缓解34.8%、疾病进展4.3%。结论认为疗效数据令人鼓舞,但研究招募严重不足,并强调需要标准化肽受体放射性核素治疗流程。

要点

  • 40例中39例为胃肠胰神经内分泌肿瘤,1例为肺神经内分泌肿瘤。
  • 末次联合周期结束时无进展生存率91.7%,末次随访时95.0%。
  • 胃肠胰神经内分泌肿瘤客观缓解率末次周期结束时27.3%,末次随访时36.8%。

核心结论

  • 尽管PRELUDE研究招募严重不足,但在这一选定人群中疗效数据令人鼓舞,提示兰瑞肽联合及序贯肽受体放射性核素治疗对胃肠胰神经内分泌肿瘤患者可能有用且可行。
  • 研究还发现了在罕见病背景下评估临床实践的挑战,并强调需要标准化肽受体放射性核素治疗流程。

研究设计与样本

  • PRELUDE为国际性、非干预性、回顾性、非比较性病历分析,纳入进展期转移性或局部晚期1或2级胃肠胰或肺神经内分泌肿瘤患者。
  • 共纳入40例患者,其中胃肠胰神经内分泌肿瘤39例,肺神经内分泌肿瘤1例。
  • 主要终点为末次兰瑞肽-肽受体放射性核素治疗周期结束时的无进展生存期。
  • 次要终点包括末次可用随访时的无进展生存期、最佳总体疗效、客观缓解率、腹泻和潮红的存在与严重程度以及安全性。
  • 事后分析确定预测治疗期间客观缓解率的最佳治疗前肿瘤生长速率截断值。

主要发现

  • 末次兰瑞肽-肽受体放射性核素治疗周期结束时无进展生存率为91.7%,末次可用随访时为95.0%。
  • 在 full analysis set 中,胃肠胰神经内分泌肿瘤患者(n=23)最佳总体疗效为疾病稳定14例(60.9%)、部分缓解8例(34.8%)、疾病进展1例(4.3%)。
  • 客观缓解率在末次兰瑞肽-肽受体放射性核素治疗周期结束时为27.3%,末次可用随访时为36.8%。
  • 预测上述两个时间点客观缓解率的最佳基线肿瘤生长速率截断值分别为1.18%和0.33%。
  • 基线时81.0%的患者有腹泻或潮红,多数病例保持稳定或改善;未报告药物不良反应增加。

关键数值与推荐

  • 胃肠胰神经内分泌肿瘤患者(n=23)最佳总体疗效:疾病稳定14例(60.9%)、部分缓解8例(34.8%)、疾病进展1例(4.3%)。
  • 客观缓解率:末次兰瑞肽-肽受体放射性核素治疗周期结束时27.3%,末次可用随访时36.8%。
  • 预测客观缓解率的最佳基线肿瘤生长速率截断值:末次周期结束时为1.18%,末次随访时为0.33%。
  • 基线时81.0%的患者有腹泻或潮红。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究招募严重不足(major recruitment shortfall)。
  • 研究为回顾性、非干预性、非比较性分析。
  • 研究在罕见病背景下评估临床实践存在挑战。
  • 需要标准化肽受体放射性核素治疗流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PRELUDE aimed to assess use and effectiveness/safety of lanreotide autogel/depot (LAN) combined with 177Lu-DOTATOC or 177Lu-DOTATATE (LAN-peptide receptor radionuclide therapy [PRRT]) in patients with progressive neuroendocrine tumours (NETs). METHODS: International, non-interventional, retrospective, non-comparative analysis of medical records from patients with progressive metastatic or locally advanced grade 1 or 2 gastroenteropancreatic (GEP)- or lung-NETs. The primary endpoint was progression-free survival (PFS) at end of last LAN-PRRT cycle. Secondary endpoints included PFS at last available follow-up, best overall response, objective response rate (ORR), presence and severity of diarrhoea and flushing, and safety. Post-hoc analyses were conducted to determine pre-treatment tumour growth rate (TGR) cutoffs that best predicted the ORR during treatment. RESULTS: Forty patients were enrolled (GEP-NETs, n = 39; lung-NETs, n = 1). PFS rates were 91.7% at end of last LAN-PRRT cycle and 95.0% at last available follow-up. In the full analysis set, best overall response among patients with GEP-NETs (n = 23) was stable disease (n = 14, 60.9%), partial response (n = 8, 34.8%) and progressive disease (n = 1, 4.3%). The ORR was 27.3% at end of last LAN-PRRT cycle and 36.8% at last available follow-up. Optimal baseline TGR cutoffs for predicting ORR at these time points were 1.18% and 0.33%, respectively. At baseline, 81.0% of patients had diarrhoea or flushing; both remained stable or improved in most cases. No increased adverse drug reactions were reported. CONCLUSION: Despite the major recruitment shortfall for the PRELUDE study, effectiveness data were encouraging in this selected population, highlighting the potential usefulness and feasibility of LAN combined with and after PRRT in patients with GEP-NETs. The study also identified challenges associated with evaluating clinical practice in a rare-disease setting and highlighted the need for standardisation of PRRT procedures. TRIAL REGISTRATION: Trial number: NCT02788578; URL: https://clinicaltrials.gov/ct2/show/NCT02788578.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Prasad V, Srirajaskanthan R, Toumpanakis C, et al. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. Eur J Nucl Med Mol Imaging. 2020. PMID: 32062681. doi:10.1007/s00259-020-04712-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。